Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$1.31
+0.05 (+3.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $34.7M · quality 26.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$485M
P/E
N/A
•EV/EBITDA
48.7x
↑ROE
-39.8%
↓Gross Margin
49.5%
↑Debt/Equity
1.72
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.0%
FCF CAGR
—
FCF margin
5.3%
FCF / Net income
-0.26x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $655.8M · net income $-135.4M · FCF $34.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $655.8M | $655.8M | $724.3M | $770.9M | $842.7M |
| Net Income | $-135.4M | $-135.4M | $-74.4M | $-175.5M | $-212.0M |
| EBITDA | $20.3M | $20.3M | $112.9M | $-14.0M | $-10.7M |
| EPS | -0.38 | -0.38 | -0.17 | -0.53 | -0.71 |
| Gross Margin | 49.5% | 49.5% | 50.3% | 47.0% | 48.3% |
| Operating Margin | 11.7% | 11.7% | 15.1% | 8.2% | 6.8% |
| Net Margin | -20.6% | -20.6% | -10.3% | -22.8% | -25.2% |
| Balance Sheet | |||||
| Debt/Equity | 1.72 | 1.72 | 1.35 | 1.35 | 1.07 |
| Current Ratio | 2.51 | 2.51 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $34.7M | $34.7M | $109.0M | $681000.00 | $-67.4M |
| Returns | |||||
| ROE | -39.8% | -39.8% | -15.7% | -34.7% | -33.8% |
| Valuation | |||||
| EV/EBITDA | 48.73 | 48.73 | 8.58 | — | — |
| P/B | 1.37 | 1.37 | 0.98 | 1.63 | 1.25 |
| Growth & Yield | |||||
| Revenue Growth | -9.5% | -9.5% | -6.0% | -8.5% | — |
| EPS Growth | -119.0% | -119.0% | 67.2% | 25.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+56.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.17 → -0.38
Residual
+56.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.